JP2003509468A - 癒着形成を阻害する方法および組成物 - Google Patents

癒着形成を阻害する方法および組成物

Info

Publication number
JP2003509468A
JP2003509468A JP2001524620A JP2001524620A JP2003509468A JP 2003509468 A JP2003509468 A JP 2003509468A JP 2001524620 A JP2001524620 A JP 2001524620A JP 2001524620 A JP2001524620 A JP 2001524620A JP 2003509468 A JP2003509468 A JP 2003509468A
Authority
JP
Japan
Prior art keywords
antagonist molecule
composition
monoclonal antibody
molecule
extracellular matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001524620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003509468A5 (https=
Inventor
チエレツシユ，デイビツド・エイ
レツシイ，ブルース
Original Assignee
ザ・スクリプス・リサーチ・インステイチユート
ザ・ユニバーシテイ・オブ・ノース・カロライナ・アト・チャペル・ヒル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・スクリプス・リサーチ・インステイチユート, ザ・ユニバーシテイ・オブ・ノース・カロライナ・アト・チャペル・ヒル filed Critical ザ・スクリプス・リサーチ・インステイチユート
Publication of JP2003509468A publication Critical patent/JP2003509468A/ja
Publication of JP2003509468A5 publication Critical patent/JP2003509468A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/045—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2001524620A 1999-09-23 2000-09-22 癒着形成を阻害する方法および組成物 Pending JP2003509468A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40552299A 1999-09-23 1999-09-23
US09/405,522 1999-09-23
PCT/US2000/026095 WO2001021196A1 (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Publications (2)

Publication Number Publication Date
JP2003509468A true JP2003509468A (ja) 2003-03-11
JP2003509468A5 JP2003509468A5 (https=) 2007-11-08

Family

ID=23604048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001524620A Pending JP2003509468A (ja) 1999-09-23 2000-09-22 癒着形成を阻害する方法および組成物

Country Status (9)

Country Link
EP (1) EP1223962A4 (https=)
JP (1) JP2003509468A (https=)
KR (1) KR20020048941A (https=)
CN (1) CN1399554A (https=)
AU (1) AU781442B2 (https=)
BR (1) BR0014222A (https=)
CA (1) CA2384812A1 (https=)
MX (1) MXPA02003079A (https=)
WO (1) WO2001021196A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019138583A1 (ja) * 2018-01-15 2019-07-18 持田製薬株式会社 癒着防止用組成物
US11464597B2 (en) 2016-07-13 2022-10-11 The University Of Tokyo Adhesion-preventing composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2025685T3 (da) 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
KR102318958B1 (ko) * 2019-08-08 2021-10-27 고려대학교 산학협력단 인테그린 α2β1 억제제를 유효성분으로 포함하는 조직 유착 예방 또는 치료용 약제학적 조성물
EP4126957A4 (en) * 2020-03-31 2024-07-24 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING DYSREGULATED WOUND HEALING

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010045316, Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ, 1987, ｖｏｌ．２６２， ｎｏ．３６, ｐ．１７７０３−１７７１１ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464597B2 (en) 2016-07-13 2022-10-11 The University Of Tokyo Adhesion-preventing composition
US11890145B2 (en) 2016-07-13 2024-02-06 The University Of Tokyo Adhesion-preventing composition
WO2019138583A1 (ja) * 2018-01-15 2019-07-18 持田製薬株式会社 癒着防止用組成物
JPWO2019138583A1 (ja) * 2018-01-15 2021-01-28 持田製薬株式会社 癒着防止用組成物
JP7161496B2 (ja) 2018-01-15 2022-10-26 持田製薬株式会社 癒着防止用組成物

Also Published As

Publication number Publication date
AU781442B2 (en) 2005-05-26
CA2384812A1 (en) 2001-03-29
KR20020048941A (ko) 2002-06-24
AU7985000A (en) 2001-04-24
WO2001021196A1 (en) 2001-03-29
EP1223962A4 (en) 2004-01-21
EP1223962A1 (en) 2002-07-24
MXPA02003079A (es) 2004-04-21
BR0014222A (pt) 2003-02-25
CN1399554A (zh) 2003-02-26

Similar Documents

Publication Publication Date Title
AU2016248341B2 (en) Bioconjugates and uses thereof
CA2105652C (en) Reducing wound scarring with antibodies to growth factors
TWI257307B (en) Pharmaceutical composition for cardiac tissue repair
EP3185888B1 (en) Extracellular matrix compositions
JP2001500475A (ja) 細胞接着を調節するための化合物および方法
US11529424B2 (en) Synthetic bioconjugates
JP2002512640A (ja) 持続性治療薬の局所送達
US20170368192A1 (en) Luminal vessel coating for arteriovenous fistula
CN103732234A (zh) 使伤口愈合的装置和方法
Back et al. Application of hyaluronic acid/sodium alginate-based microparticles to prevent tissue adhesion in a rabbit model
CN102405050B (zh) 抑制细胞增殖和手术粘连的方法和组合物
AU781442B2 (en) Method and compositions for inhibiting adhesion formation
Pascual et al. Behaviour at the peritoneal interface of next-generation prosthetic materials for hernia repair
EP3261672B1 (en) Molecules disrupting pyruvate kinase m2 and integrin interaction and uses thereof
JP2005272480A (ja) トロンボスポンジン−様活性を有するペプチド及びその治療のための使用
JP2012515151A (ja) 創傷、傷跡、および手術後の癒着形成を治療するためのヒアルロン酸含有組成物
AU1843495A (en) Fibrin-specific antibody for use as an antithrombotic agent
JP2006522140A (ja) 線維症の治療用ポリマー薬剤
WO2025101703A1 (en) Encapsulation and local delivery of inhibitors of the activator protein 1 (ap-1) for preventing adhesions
CN121944252A (zh) 一种多糖-抗菌肽共组装水凝胶及其制备方法与应用
US9566297B2 (en) Methods and compositions for inhibiting cellular proliferation and surgical adhesion
Ettinger Bladder reconstruction with amniochorion
JP2000095706A (ja) 経皮的冠動脈形成術後再狭窄防止用薬剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110201